On June 3, the United States Court of Appeals for the Ninth Circuit issued their decision that effectively vacated the registrations of the dicamba-containing products XtendiMax, Engenia and FeXapan. Since this ruling many questions have arisen, including the fate of these products already in the commercial channel. During a recent conversation with officials at the Illinois Department of Agriculture, officials presented their interpretation of the court ruling as follows:
It is the current interpretation of the Illinois Department of Agriculture that the dicamba-containing products XtendiMax, Engenia and FeXapan are no longer registered products and are not to be distributed, sold or used, effective upon the decision of the United States Court of Appeals for the Ninth Circuit.
The registration of Tavium and all other dicamba-containing products are not affected by this ruling.
Source: Aaron Hager, University of Illinois